Health Trials

Bronchiectasis With Pseudomonas Aeruginosa Colonization

3

Review clinical trials related to Bronchiectasis With Pseudomonas Aeruginosa Colonization. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Participants needed: 84
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Aug 19, 2026Locations: 40
Eligibility criteria

Participant must be ≥ 18 years of age at the time of signing the informed consen... [+8]

Primary lung diagnosis other than bronchiectasis [+11]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Participants needed: 435
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Aug 18, 2026Locations: 187
Eligibility criteria

Participant must be ≥ 12 years of age at the time of signing the informed consen... [+8]

Primary lung diagnosis other than bronchiectasis [+11]

Read more
Status: Recruiting

First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

Participants needed: 104
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Centauri Therapeutics LimitedUpdated: Jul 16, 2026Locations: 1
Eligibility criteria

Parts A and B: Healthy adult males and/or females, 18 to 65 years of age. [+6]

Parts A and B: Previous participation in the current trial. [+9]

Read more